Pro-inflammatory cytokine inhibition in the primate using microencapsulated antisense oligomers to NF-κB

References

• Arnalich F, Garcia-Palomero E, Lopez J, Jimenez M, Madero R, Renart J, Vazquez J, Montiel C. Predictive value of nuclear factor κB activity and plasma cytokine levels in patients with sepsis. Infection and Immunity 2000; 68: 1942–1945
   PubMed Web of Science ®Google Scholar
• Abraham E, Laterre P, Garbino J. Eternercept (p55 tumor necrosis factor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Critical Care Medicine 2001; 29: 503–508
   PubMed Web of Science ®Google Scholar
• Bagby GJ, Plessala KJ, Wilson LA, Thompson JJ, Nelson S. Divergent efficacy of antibody to tumor necrosis factor-α in intravascular and peritonitis models of sepsis. Journal of Infectious Diseases 1991; 163: 83–88
   PubMed Web of Science ®Google Scholar
• Bender A, Schafer V, Steffan A, Royer C, Rubsamen-Waigmann H, von Briesen H. Inhibition of HIV in vitro by antiviral drug targeting using nanoparticles. Research Virology 1994; 145: 215–220
   PubMedGoogle Scholar
• Bohrer H, Qiu F, Zimmerman T, et al. Role of NF-κB in the mortality of sepsis. Journal of Clinical Investigation 1997; 100: 972–985
   PubMed Web of Science ®Google Scholar
• Bathon J, Martin R, Fleishmann R. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. The New England Journal of Medicine 2000; 343: 1586–1602
   PubMed Web of Science ®Google Scholar
• Cohen P, Nakshatri H, Dennis J, Caragine T, Bianchi M, Cerami A, Tracey K. CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency. Proceedings of the National Academy of Science USA 1996; 93: 3967–3971
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Okusawa S, Gelfand JA. Interleukin-1 induces a shock-like state in rabbits: Synergism with tumor necrosis factor and the effect of ibuprofen. Progress in Clinical Biological Research 1989; 299: 203–215
   PubMedGoogle Scholar
• D'souza MJ, DeSouza P. Site-specific microencapsulated drug targeting strategies–liver and gastro-intestinal tract targeting. Advanced Drug Delivery Reviews 1995; 17: 247–254
   Web of Science ®Google Scholar
• D'souza MJ, Oettinger CW, Milton G. Evaluation of microspheres containing cytokine neutralizing antibodies in endotoxemia. Drug Developement and Industrial Pharmacy 1999a; 25: 727–734
   PubMed Web of Science ®Google Scholar
• D'souza MJ, Oettinger CW, Milton G, Tracey K. Prevention of lethality and suppression of pro-inflammatory cytokines in experimental septic shock by microencapsulated CNI-1493. Journal of Interferon and Cytokine Research 1999b; 19: 1125–1133
   PubMed Web of Science ®Google Scholar
• D'souza MJ, Oettinger CW, Shah A, Tipping PG, Huang XR, Milton GV. Macrophage depletion by albumin microencapsulated clodronate: Attenuation of cytokine release in macrophage-dependent glomerulonephritis. Drug Development and Industrial Pharmacy 1999c; 25: 591–598
   PubMed Web of Science ®Google Scholar
• D'souza MJ, Oettinger CW, Milton G. Microspheres containing neutralizing antibodies to tumor necrosis factor α an d interleukin-1β protect rats from Staphylococcus aureus-induced peritonitis. Journal of Interferon and Cytokine Research 2000; 20: 907–913
   PubMed Web of Science ®Google Scholar
• D'souza MJ, Zhaowei J, Oettinger CW. The treatment of experimental septic shock with microencapsulated antisense oligomers to NF-κB. Journal of Interferon and Cytokine Research 2005; 25: 15–24
   Web of Science ®Google Scholar
• Epstein F. Nuclear factor-κB- A pivotal transcription factor in chronic inflammatory diseases. NEJM 1997; 336: 1066–1071
   PubMed Web of Science ®Google Scholar
• Ghosh C, Iversen P. Intracellular delivery strategies for antisense phosphorodiamidate morpholino oligomers. Antisense & Nucleic Acid Drug Development 2000; 10: 263–274
   PubMedGoogle Scholar
• Ghosh S, May MJ, Kopp EB. Annual Review of Immunology 1998; 16: 225–260
   PubMed Web of Science ®Google Scholar
• Gharaee-Kermani M, Phan S. Role of cytokines and cytokine therapy in wound healing and fibrotic diseases. Current Pharmaceutical Design 2001; 7: 1083–1103
   PubMed Web of Science ®Google Scholar
• Hinshaw LB, Emerson TE, Taylor FB, et al. Lethal Staphylococcus aureus-induced shock in primates: Prevention of death with anti-TNF antibody. Journal of Trauma 1992; 33: 568–573
   PubMed Web of Science ®Google Scholar
• Hinshaw LB, Emerson TE, Chang AC, Duerr M, Peer G, Fournel M. Study of septic shock in the non-human primate: Relationship of pathophysiological response to therapy with anti-TNF antibody. Circulatory Shock 1994; 44: 221–229
   PubMedGoogle Scholar
• Hinshaw LB, Tekamp-Olson P, Chang ACK, Lee PA, Taylor FB, Murray CK, Peer GT, Emerson TE, Passey RB, Kuo GC, et al. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNFα). Circulatory Shock 1990; 30: 279–292
   PubMedGoogle Scholar
• Issekutz AC, Issekutz TB. Quantitation and kinetics of blood monocyte migration to acute inflammatory reactions, and IL-1α, tumor necrosis factor-α, and IFN-γ. The Journal of Immunology 1993; 151: 2105–2115
   PubMed Web of Science ®Google Scholar
• Kinasewitz GT, Chang ACK, Peer GT, Hinshaw LB, Taylor FB. Peritonitis in the baboon: A primate model which simulates human sepsis. Shock 2000; 13: 100–109
   PubMed Web of Science ®Google Scholar
• Mercurio F, Manning AM. Multiple signals converging on NF-κB. Current Opinion in Cell Biology 1999; 11: 226–232
   PubMed Web of Science ®Google Scholar
• Oliver J, Bland L, Oettinger CW, Arduino M, McAllister S, Aguero S, Favero M. Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge. Lymphokine and Cytokine Research 1993; 12: 115–120
   PubMedGoogle Scholar
• Oettinger CW, D'souza MJ. Targeting macrophages with microspheres containing cytokine-neutralizing antibodies prevents lethality in gram-negative peritonitis. Journal of Interferon and Cytokine Research 1999; 19: 33–40
   PubMed Web of Science ®Google Scholar
• Oettinger CW, D'souza MJ. Microencapsulation of tumor necrosis factor oligomers: A new approach to pro-inflammatory cytokine inhibition. Journal of Interferon and Cytokine Research 2003; 23: 533–543
   PubMed Web of Science ®Google Scholar
• Pahl H. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999; 18: 6853–6866
   PubMed Web of Science ®Google Scholar
• Paterson RL, Galley HF, Dhillon JK, Webster NR. Increased nuclear factor-κB activation in critically ill patients who die. Critical Care Medicine 2000; 28: 1047–1051
   PubMed Web of Science ®Google Scholar
• Reinhart K, Karzai W. Anti-tumor necrosis factor therapy in sepsis. Update on clinical trials and lessons learned 2001; 29: S121–125
   Google Scholar
• Silva TA, Bayston KF, Cohen J. Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-α in experimantal gram-negative shock. Journal of Infectious Diseases 1990; 162: 421–427
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bryant AE, Hackett SP, Chang A, Peer G, Kosanke S, Emerson T, Hinshaw T. Group A streptococcal bacteremia: The role of tumor necrosis factor in shock and organ failure. Journal of Infectious Diseases 1995; 173: 619–626
   Web of Science ®Google Scholar
• Sakurai H, Hisada Y, Ueno M, Sugiura M, Kawashima K, Sugita T. Activation of transcription factor NF-κB in experimental glomerulonephritis in rats. Biochimica et Biophysica Acta 1996; 1316: 132–138
   PubMed Web of Science ®Google Scholar
• Tracey KJ, Lowry S, Fahey T, Albert J, Fong Y, Hesse D, Beutler B, Manogue K, Calvano S, Wei H, et al. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surgery, Gynecology & Obstetrics 1987; 164: 415–422
   PubMedGoogle Scholar
• Targan S, Hanauer S, Sander J. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Chrone's disease. The New England Journal of Medicine 1997; 337: 1029–1035
   PubMed Web of Science ®Google Scholar
• von Hoegen I, Waller C. Safety of human albumin based on spontaneously reported serious adverse events. Critical Care Medicine 2001; 29: 994–996
   PubMed Web of Science ®Google Scholar
• Vincent J-L, Navickis RJ, Wilkes MM. Morbidity in hospitalized patients receiving human albumin: A meta-analysis of randomized, controlled trials. Critical Care Medicine 2004; 32: 2029–2038
   PubMed Web of Science ®Google Scholar
• Waage A, Espevik T. Interleukin-1 potentiates the lethal effect of tumor necrosis factor α/cachcectin in mice. Journal of Experimental Medicine 1988; 167: 1987–1992
   PubMed Web of Science ®Google Scholar
• Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock. A reassessment 1997; 25: 1095–1100
   Google Scholar
• Zingarelli B, Sheehan M, Wong H. Nuclear factor-kB as a therapeutic target in critical care medicine. Critical Care Medicine 2000; 31: S105–S111
   Web of Science ®Google Scholar
• Zanotti S, Kumar A, Kumar A. Cytokine modulation in sepsis and septic shock. Expert Opinion Investig Drugs 2002; 11: 1061–1075
   PubMed Web of Science ®Google Scholar